Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis

Systemic methotrexate for the treatment of psoriasis

“…However, both pharmacokinetics and pharmacodynamics are also strongly influenced by interactions with concomitant medications, renal function or patient's age [39]. A better knowledge of these pharmacokinetic and pharmacogenetic variations might be useful to tailor the dose for each patient and predict the response in patients receiving MTX [14,66]. However, a careful evaluation of the concomitant medications, age, renal and hepatic function, cognitive status and comorbidities should be performed to prevent adverse events related with the administration of MTX.…”

Multidrug resistance 1 (MDR1) 3435C>T gene polymorphism influences the clinical phenotype and methotrexate-induced adverse events in South Indian Tamil rheumatoid arthritis

“…Maja Bulatovic et al[43] developed a prediction model comprising genetic and clinical variables to identify JIA patients not responding to methotrexate. Here, MDR1 3435C>T was associated with a higher probability of good clinical response to methotrexate.…”

Novel insights in folate receptors and transporters: implications for disease and treatment of immune diseases and cancer

“…With the use of a personalized-medicine approach, genetic variations (SNPs) and metabolites (folate, MTX-polyglutamates) within the MTX pathway (one-carbon fingerprint) were analyzed to predict the outcome of MTX treatment in RA. Beyond clinical parameters (body mass index, smoking) and baseline disease severity, genetic factors that were associated with unresponsiveness to MTX included SNPs in the efflux transporters ABCB1 (rs1045642 G > A) and ABCC3 (rs4793665 T > C), and methionine synthesis (MTRR, rs1801394 A > G) [90,91]. Furthermore, low baseline erythrocyte folate and erythrocyte MTX-polyglutamate levels after 3 months of treatment were predictive for a decreased MTX response [92].…”